EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Closing the Gaps: Testing the Efficacy of Carbapenem and Cephalosporin Treatments of Late-Stage Anthrax in Rabbits

Assa Sittner iD, Elad Bar-David, Itai Glinert, Amir Ben-Shmuel, Josef Schlomovitz, Haim Levy iD, Shay Weiss

Pathogens · 2024

DOI: 10.3390/pathogens13110936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Assa Sittner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona P.O. Box 19, Israel. Hauptthemen laut MEDLINE: Anthrax, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Institute for Biological Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anthrax is a fatal zoonotic disease caused by exposure to Bacillus anthracis spores. The CDC’s guidelines divide anthrax treatment into three categories according to disease progression: post-exposure prophylaxis (PEP), systemic, and systemic with a suspicion of CNS infection. While the prognosis for PEP or the early treatment of systemic anthrax is very good, ingress of the bacteria into the CNS poses a substantial clinical challenge. Here, we use rabbits to test the efficacy of a combined treatment of meropenem and doxycycline, which is the first choice in the CDC recommendations for treating systemic patients with an indication of CNS infection. In addition, we test the efficacy of the first-generation cephalosporin, cefazolin, in treating different stages of the disease. We found that the combination of doxycycline and meropenem is highly effective in treating rabbits in our inhalation model. Cefazolin was efficient only for PEP or systemic-stage treatment and not for CNS-infected animals. Our findings support the CDC recommendation of using a combination of doxycycline and meropenem for systemic patients with or without indications of CNS infection. We found that cefazolin is a decent choice for PEP or early-stage systemic disease but recommend considering using this antibiotic only if all other options are not available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraxAnti-Bacterial AgentsAnimalsRabbitsDisease Models, AnimalDoxycyclineDrug Therapy, CombinationBacillus anthracisCefazolinCephalosporinsCarbapenemsMeropenemTreatment OutcomePost-Exposure Prophylaxis

Stichwörter der Autor:innen

Bacillus anthracisCDC guideline: CNS infectionanthraxantibiotic treatmentcefazolindoxycyclinemeropenem

Substanzen

Anti-Bacterial AgentsDoxycyclineCefazolinCephalosporinsCarbapenemsMeropenem

Autor:innen und Institutionen

  • Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona P.O. Box 19, Israel.

ORCID-Profile: Assa Sittner, Haim Levy

Förderung

  • Israel Institute for Biological Research

Zitieren

APA

Sittner, A., Bar-David, E., Glinert, I., Ben-Shmuel, A., Schlomovitz, J., Levy, H., & Weiss, S. (2024). Closing the Gaps: Testing the Efficacy of Carbapenem and Cephalosporin Treatments of Late-Stage Anthrax in Rabbits. Pathogens. https://doi.org/10.3390/pathogens13110936

Vancouver

Sittner A, Bar-David E, Glinert I, Ben-Shmuel A, Schlomovitz J, Levy H, et al. Closing the Gaps: Testing the Efficacy of Carbapenem and Cephalosporin Treatments of Late-Stage Anthrax in Rabbits. Pathogens. 2024. doi:10.3390/pathogens13110936

BibTeX
@article{Sittner2024,
  author = {Sittner, Assa and Bar-David, Elad and Glinert, Itai and Ben-Shmuel, Amir and Schlomovitz, Josef and Levy, Haim and Weiss, Shay},
  title = {Closing the Gaps: Testing the Efficacy of Carbapenem and Cephalosporin Treatments of Late-Stage Anthrax in Rabbits},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13110936}
}
Kostenlos starten →